Evidence map›Paper›PMID 37795159›Full record

ArticleMateria socio-medica2023

The Comparative Study of the Administration of the Combination Preparation of Isoflavones and Hyaluronic Acid in Menopausal Women for the Treatment of the Symptoms of Menopause, Urogenital Atrophy and Oteoporosis in Relation to Existing Hormone Replacement Therapies.

Anna Chalkidou, Efthimios Oikonomou, Dimitrios Lambrinos, Anastasia Bothou, Dimitrios Kyriakou, Konstantinos Nikolettos, Georgios Marinos, Georgios Iatrakis, Stefanos Zervoudis, Nikolaos Nikolettos and 1 more

Open access · greenAbstract read
In one paragraph

Article in Materia socio-medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Anna ChalkidouDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Efthimios OikonomouDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Dimitrios LambrinosEmergency Care Department, Laiko General Hospital, Athens, Greece.
Anastasia BothouDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Dimitrios KyriakouDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Konstantinos NikolettosDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Georgios MarinosGeorgios Marinos, Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Georgios IatrakisDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Stefanos ZervoudisDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Nikolaos NikolettosDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Panagiotis TsikourasDepartment of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Democritus University of Thrace · GRLaiko General Hospital of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Menopause is characterized by a series of symptoms and effects from the various systems and organs, for which, the decline in estrogen production from the ovaries is considered responsible. Objective: The aim of this study was to make comparative study of the administration of the combination preparation of isoflavones and hyaluronic acid in menopausal women for the treatment of the symptoms of menopause, urogenital atrophy and osteoporosis in relation to existing hormone replacement therapies. Methods: In this five-year, double-blind, placebo-controlled clinical study, a total of 274 postmenopausal women were enrolled and classified into three groups. Participants in group A, were 96 women who did not receive Hormone Replacement Therapy (HRT), in the second group, 92 received daily treatment with tibolone (2.5 mg) as monotherapy, and in the third group, 86 received treatment with a pharmaceutical formulation of hyaluronic acid 120 mg and isoflavones. MF11RCE 80 mg. Results: In the postmenopausal women of our study, a significant reduction of postmenopausal symptoms was found in both groups B and C of participants who received hormone replacement preparations compared to group A who did not receive HRT. Furthermore, no difference in efficacy was observed between the administered preparations of isoflavones and tibolone. Conclusion: The combination of isoflavones and hyaluronic acid has the same efficacy as tibolone in menopausal symptoms.

Indexed as

climacteric symptomshormone replacement therapyhyaluronic acidisoflavonestreatment options

Identifiers

PMID37795159
PMCPMC10545921
OpenAlexW4386804362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.